Virbac : Declaration of the number of shares and voting rights 06/2023
Read moreUltimate Guide: Everything You Need to Know About Industry 4.0 …
Read moreUltimate Guide: Everything You Need to Know About Industry 4.0 …
Read moreUltimate Guide: Everything You Need to Know About Industry 4.0 …
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage…
SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) — Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage…
SYDNEY, AUSTRALIA, Sept. 05, 2023 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”…
SYDNEY, AUSTRALIA, Sept. 05, 2023 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep”…
SOLANA BEACH, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a…
SOLANA BEACH, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a…
Read moreUltimate Guide: Everything You Need to Know About Industry 4.0 …
Read moreUltimate Guide: Everything You Need to Know About Industry 4.0 …
Read moreUltimate Guide: Everything You Need to Know About Industry 4.0 …
Read moreUltimate Guide: Everything You Need to Know About Industry 4.0 …
MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the…
MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the…
LAWRENCEVILLE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology…
LAWRENCEVILLE, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) — IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage biotechnology…
RHONDOS On Demand Generally Available for all SAP Applications PORTLAND, Ore., Sept. 05, 2023 (GLOBE…
New Strategic Relationship Expands US Addressable Audience To More Than 150 Million LOS ALAMITOS, Calif….
VANCOUVER, British Columbia, Sept. 05, 2023 (GLOBE NEWSWIRE) — Interfield Global Software Inc. (NEO: IFSS)…
Common equity investment by Fortress accelerates Nassau’s growth plans Provides full access to Fortress investment…